机构：[1]Department of Ophthalmology, Tongliao City Hospital, Tongliao, China[2]State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China[3]Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts[4]Department of Ophthalmology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China[5]Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, Kunming, China外科科室眼科昆明医科大学附属第一医院[6]Kunming Medical University, Kunming, China[7]Aier School of Ophthalmology, Central South University, Changsha, China.
Objectives: To evaluate the short-term efficacy of triamcinolone acetonide versus bevacizumab for the treatment of diabetic, clinically significant, macular edema with different optical coherence tomography findings. Methods: Fifty eyes of 45 consecutive patients with diabetic, clinically significant, macular edema were incorporated in this prospective interventional case series. Patients were divided into 3 groups according to findings on optical coherence tomography: 1) macular edema combined with serous retinal detachment (Group 1), 2) diffused macular thickening (Group 2), and 3) cystoid macular edema (Group 3). Patients from each group were treated with a single intravitreal injection of triamcinolone (IVTA) or 2 intravitreal injections of bevacizumab (IVB) with an interval of 6 weeks. Patients were observed at 6, 12, and 24 weeks after IVTA or the first IVB injection. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were examined at each visit. Repeated-measures analysis of variance was used to compare the efficacy of the treatment groups. Results: In Group 1, IVTA showed more favorable effects on CRT reduction and BCVA improvement compared with IVB at 6, 12, and 24 weeks (P = 0.002, 0.001, 0.027 and P = 0.036, 0.001, 0.027), respectively. In Group 2, IVB had more CRT reduction than IVTA at 6 and 12 weeks (P = 0.013 and 0.036), although there was no significant difference in BCVA improvement between the 2 groups (p > 0.05). In Group 3, IVTA and IVB did not have significant effects on CRT reduction and BCVA improvement (p > 0.05). Conclusion: The short-term efficacy of IVTA and IVB on treating clinically significant macular edema varied with different optical coherence tomography findings. In clinically significant macular edema combined with serous retinal detachment, IVTA may be more favorable than IVB in CRT reduction and BCVA improvement. In patients with diffused macular thickening, IVB may be better than IVTA in macular thickness reduction, although this does not translate to a significant improvement in BCVA.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81260151]; Applied Basic Research Foundation of the Department of Science and Technology of Yunnan Province [2011FB062]; Science and Technology Foundation of the Department of Health of Yunnan Province [2011WS0041]
第一作者机构：[1]Department of Ophthalmology, Tongliao City Hospital, Tongliao, China
共同第一作者：
通讯作者：
通讯机构：[5]Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, Kunming, China[*1]Aier School of Ophthalmology, Central South University, Fourth Floor, New Century Mansion, 198 Middle Furong Road, Changsha 410015, China
推荐引用方式(GB/T 7714)：
Liu Qingyun,Hu Yijun,Yu Honghua,et al.COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA[J].RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES.2015,35(2):272-279.doi:10.1097/IAE.0000000000000300.
APA：
Liu, Qingyun,Hu, Yijun,Yu, Honghua,Yuan, Ling,Hu, Jie...&Tang, Shibo.(2015).COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA.RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES,35,(2)
MLA：
Liu, Qingyun,et al."COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA".RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES 35..2(2015):272-279
